Capital International Inc. CA Trims Stock Position in Catalent, Inc. (NYSE:CTLT)

Capital International Inc. CA reduced its stake in Catalent, Inc. (NYSE:CTLT) by 36.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,502 shares of the company’s stock after selling 7,888 shares during the quarter. Capital International Inc. CA’s holdings in Catalent were worth $762,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Vanguard Group Inc. grew its position in Catalent by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock valued at $1,151,872,000 after buying an additional 218,682 shares during the last quarter. Capital World Investors boosted its holdings in Catalent by 6.1% in the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after purchasing an additional 1,098,474 shares in the last quarter. Nomura Holdings Inc. increased its position in Catalent by 149.4% during the 4th quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after purchasing an additional 6,881,914 shares during the period. Cadian Capital Management LP raised its stake in shares of Catalent by 14.3% during the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock worth $272,473,000 after buying an additional 759,600 shares in the last quarter. Finally, Capital International Investors lifted its holdings in shares of Catalent by 1.2% in the 4th quarter. Capital International Investors now owns 2,994,467 shares of the company’s stock valued at $134,541,000 after buying an additional 34,856 shares during the period.

Insider Activity

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the sale, the insider now directly owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Catalent news, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the transaction, the chief financial officer now directly owns 33,871 shares in the company, valued at approximately $1,921,840.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the sale, the insider now owns 20,617 shares in the company, valued at approximately $1,118,678.42. The disclosure for this sale can be found here. Company insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Barclays increased their price objective on Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. StockNews.com assumed coverage on shares of Catalent in a report on Wednesday. They issued a “sell” rating for the company. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Catalent presently has a consensus rating of “Hold” and an average target price of $55.65.

Catalent Price Performance

CTLT traded up $0.23 during midday trading on Friday, reaching $58.68. 3,004,922 shares of the company’s stock were exchanged, compared to its average volume of 1,818,650. The business’s 50-day moving average price is $56.21 and its 200 day moving average price is $55.69. The stock has a market capitalization of $10.62 billion, a PE ratio of -9.62, a P/E/G ratio of 2.41 and a beta of 1.16. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $60.20. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. As a group, equities analysts anticipate that Catalent, Inc. will post -0.17 EPS for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.